OSTX

OS Therapies Inc

0.7450

Nov 13 • 3:57 PM ET -0.0051 (-0.68%)

0.7450

Aftermarket • 7:30 PM ET 0.0000 (0.00%)

Healthcare Biotechnology USA Nano AMEX

Nov 13, 8:36 AMOS Therapies receives approximately $900,000 in UK R&D tax credits

Peers: GLSI ANIX ELTX PDSB ONCY BCTX SLS HURA MAIA IMNN

| Held by: VTI VXF IWC BUSM

Scroll to Statements

Index	-
Market Cap	38.98M
Enterprise Value	39.84M
Income	-39.37M
Sales	0.00M
Book/sh	-0.26
Cash/sh	0.00
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	5
IPO	Aug 01, 2024

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	-
P/C	185.62
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.18
Current Ratio	0.18
Debt/Eq	-
LT Debt/Eq	-
Option/Short	No / Yes

EPS (ttm)	-1.04
EPS next Y	-0.19
EPS next Q	-0.14
EPS this Y	24.74%
EPS next Y	74.24%
EPS next 5Y	-
EPS past 3/5Y	-47.63% 67.91%
Sales past 3/5Y	- -
EPS Y/Y TTM	-41.63%
Sales Y/Y TTM	-
EPS Q/Q	-8.86%
Sales Q/Q	-
Earnings	Aug 14 BMO
EPS/Sales Surpr.	-12.36% -

Insider Own	6.55%
Insider Trans	0.00%
Inst Own	4.99%
Inst Trans	2.87%
ROA	-389.65%
ROE	-914.04%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-32.72%
SMA50	-47.99%
SMA200	-51.59%
Trades

Shs Outstand	52.32M
Shs Float	48.89M
Short Float	5.65%
Short Ratio	3.99
Short Interest	2.76M
52W High	2.25 -66.89%
52W Low	0.58 28.47%
Volatility	16.11% 13.26%
ATR (14)	0.13
RSI (14)	16.43
Beta	-0.35
Rel Volume	1.19
Avg Volume	691.65K
Volume	821,972

Perf Week	-25.50%
Perf Month	-47.16%
Perf Quarter	-49.32%
Perf Half Y	-60.37%
Perf YTD	-46.79%
Perf Year	-59.07%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	8.25
Prev Close	0.75
Price	0.75
Change %	-0.68%

Consensus

Strong Buy

Avg. Price Target

$8.25

Implied Upside

+1,007.4%

Analysts2incl. previous ratings

Rating Distribution2 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jul 09, 2026	Initiated	RRoth Capital	Buy	$7	+839.6%
Apr 02, 2025	Initiated	LLake Street	Buy	$19	+2,450.3%

Nov-13-26 08:30AM	OS Therapies Announces Shelving of U.S. FDA Commissioner's National Priority Voucher Has No Impact on the Company (Newsfile Corp.)
Nov-10-26 08:15AM	OS Therapies Initiates U.K. MHRA Conditional Marketing Authorisation Application for Herlystic (OST-HER2) in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
Nov-05-26 08:00AM	OS Therapies Completes Requalification of Phase 2b Herlystic (OST-HER2) Drug Substance for Confirmatory Phase 3 Trial (Newsfile Corp.) -14.77%
Oct-19-26 08:30AM	OS Therapies Announces Initial Closing of Warrant Exercise Inducement and Exchange Offer for Initial Gross Proceeds of Approximately $7.2 Million (Newsfile Corp.)
Oct-07-26 08:30AM	OS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine Osteosarcoma (Newsfile)
08:30AM	Loading…
Oct-06-26 08:30AM	OS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma Trial (Newsfile) -6.88%
Oct-01-26 08:30AM	OS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer (Newsfile Corp.)
Sep-24-26 08:22AM	OS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac) (Newsfile Corp.)
Sep-21-26 06:30AM	OS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbis (Newsfile Corp.)
Sep-17-26 06:00AM	OS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Program (Newsfile Corp.)
Sep-15-26 07:46AM	OS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filing (Newsfile Corp.)
Sep-08-26 06:00AM	OS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma Trial (Newsfile Corp.)
Sep-02-26 07:20AM	OS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendance (Newsfile Corp.)
Aug-17-26 07:40AM	OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates (Newsfile Corp.) -9.26%
Aug-13-26 08:45AM	OS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
09:00AM	Loading…
Jul-08-26 09:00AM	OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program (Newsfile Corp.) -8.18%
Jul-06-26 09:00AM	OS Therapies Third Quarter 2026 Corporate Outlook (Newsfile Corp.) -14.81%
Jul-02-26 07:30AM	OS Therapies Appoints Dr. Craig Eagle to Board of Directors (Newsfile Corp.)
Jun-30-26 07:40AM	OS Therapies Provides U.S. Regulatory Update (Newsfile Corp.) -15.18%
Jun-26-26 07:40AM	OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma (Newsfile Corp.)
Jun-08-26 06:00AM	OS Therapies Achieves Global Regulatory Alignment on Design of Phase 3 Trial of OST-HER2 in Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
Jun-02-26 06:25AM	OS Therapies to report significant survival benefit for OST-HER2 in osteosarcoma (Investing.com)
06:00AM	OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
May-29-26 07:20AM	OS Therapies Announces the Publication of Four Articles on OST-HER2 and Osteosarcoma in Drug Discovery World (Newsfile Corp.) +8.08%
May-26-26 07:40AM	OS Therapies to Attend Upcoming Medical, Financial and Industry Conferences (Newsfile Corp.)
May-18-26 06:30AM	OS Therapies Reports First Quarter 2026 Financials and Provides Business Update (Newsfile Corp.) -7.98%
May-15-26 04:05PM	OS Therapies to Announce First Quarter 2026 Financials on Monday, May 18, 2026 (Newsfile Corp.)
May-14-26 07:30AM	OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical Advisor (Newsfile Corp.) +5.03%
May-12-26 02:35PM	Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) (Newsfile)
Apr-30-26 06:00AM	OS Therapies Announces EMA Initiates Rolling Review of Conditional Marketing Authorization Application for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
04:01PM	Loading…
Apr-27-26 04:01PM	OS Therapies Schedules OST-HER2 Pharmacodynamic Response Biomarker Conference Call on April 30, 2026 at 8:30am ET (Newsfile Corp.) -7.91%
Apr-16-26 07:20AM	OS Therapies Files New Patent Application Covering Biomarkers of the Immune Response to Listeria Monocytogenes (Newsfile Corp.)
Apr-13-26 06:00AM	OS Therapies Appoints Biotech Industry Luminary Robert "Bob" S. Langer, PhD as Strategic Advisor (Newsfile)
Apr-08-26 11:38AM	OS Therapies Appoints Craig Eagle, MD as Strategic Advisor (Newsfile Corp.)
Apr-02-26 05:15PM	OS Therapies Completes $5.25M Registered Direct Offering Primarily with Pre-Existing High-Net-Worth Investors (Newsfile Corp.) -6.62%
Mar-31-26 07:40AM	OS Therapies Completes Submission of Biomarker & Clinical Data for U.S. FDA Pre-BLA Meeting, Reports Full Year 2025 Financial Results and Provides Business Update (Newsfile Corp.) +6.02%
Mar-27-26 06:00AM	OS Therapies Granted Meetings with U.S. FDA, U.K. MHRA, EMA and Australian Therapeutic Goods Administration to Review Global Confirmatory Phase 3 Trial for OST-HER2 in Metastatic Osteosarcoma (Newsfile Corp.)
Mar-25-26 06:00AM	OS Therapies Granted EMA's Advanced Therapy Medicinal Product (ATMP) Designation for OST-HER2 in the Treatment of Pulmonary Recurrence in Resected Osteosarcoma (Newsfile Corp.)
Mar-09-26 07:40AM	OS Therapies Announces FDA OST-HER2 Type D Meeting Elevated to Type B Pre-BLA Meeting (Newsfile Corp.) +8.92%
Feb-17-26 09:01AM	OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings (Benzinga)
06:00AM	OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma (Newsfile Corp.)
Feb-04-26 12:45PM	OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies (Newsfile Corp.) -5.67%
Feb-02-26 06:00AM	OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
Jan-15-26 12:30PM	OS Therapies Bone Cancer Trial Data Strengthens FDA Case (Benzinga) -5.81%
07:00AM	OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile Corp.)
Jan-14-26 07:00AM	OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary (Newsfile Corp.)
Jan-12-26 08:01AM	OS Therapies Enters into Warrant Inducement Agreements (Newsfile Corp.) -7.10%
Jan-05-26 07:40AM	OS Therapies Provides First Half 2026 Corporate Outlook (Newsfile Corp.) +7.46%
Dec-15-25 06:00AM	OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (TMX Newsfile) -7.73%
Dec-09-25 07:40AM	OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (TMX Newsfile)
Dec-05-25 08:01AM	OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility (TMX Newsfile) +5.49%
Nov-25-25 09:21AM	OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization (TMX Newsfile)
Nov-21-25 04:15PM	Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25 (TMX Newsfile) +5.56%
Nov-20-25 07:40AM	OS Therapies to Spinoff OS Animal Health into Standalone Public Company (TMX Newsfile)
Nov-17-25 06:00AM	OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update (TMX Newsfile)
Oct-22-25 09:15AM	OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (TMX Newsfile)
Aug-14-25 05:44PM	OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025 (Newsfile) +14.36%
Aug-07-25 09:00AM	OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile)
06:00AM	OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Newsfile)
Jul-16-25 06:51PM	Cancer Pipeline Milestones Coming Fast as Regulators Revisit Research Priorities (PR Newswire) +6.33%
Jul-14-25 07:40AM	OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer (Newsfile) -8.24%
Jul-10-25 07:40AM	OS Therapies Provides Clinical & Global Regulatory Updates (Newsfile)
Jul-03-25 07:40AM	OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma (Business Wire)
Jun-30-25 06:00AM	OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference (Business Wire)
Jun-26-25 11:44AM	The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? (PR Newswire)
Jun-24-25 07:40AM	OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma (Business Wire)
Jun-23-25 08:29PM	OS Therapies Announces Warrant Exercise Inducement & Exchange Offer (Business Wire)
Jun-10-25 07:40AM	OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma (PR Newswire)
Jun-06-25 07:30AM	OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma (Business Wire)
May-16-25 06:00AM	OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update (Business Wire)
May-15-25 06:00AM	OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma (Business Wire) -7.78%
May-07-25 08:45AM	OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040 (Business Wire) -21.37%
May-02-25 09:32AM	Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies (Business Wire) +5.70%
Apr-22-25 07:40AM	OS Therapies FDA Meeting Request Granted (Business Wire)
Apr-14-25 10:15AM	With Young Adult Cancer on the Rise, New Therapies Spark Investor Buzz (PR Newswire)
Apr-10-25 07:42AM	OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans (Business Wire) -16.42%
Apr-09-25 07:40AM	OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals (Business Wire)
Apr-07-25 06:00AM	OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma (Business Wire)
Apr-02-25 07:40AM	OS Therapies to Host Analyst Day at NYSE on April 7, 2025 (Business Wire) +13.53%
Mar-31-25 04:30PM	OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update (Business Wire) -13.64%
07:40AM	OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma (Business Wire)
Mar-25-25 07:40AM	OS Therapies OST-HER2 Immunotherapy for Osteosarcoma Featured in Upcoming Movie Shelter Me: The Cancer Pioneers (Business Wire) -5.36%
Mar-23-25 08:49AM	OS Therapies (OSTX): Among the Penny Stocks With Huge Upside Potential According to Analysts (InsiderMonkey)
Mar-21-25 07:40AM	OS Therapies to Attend The Jones Healthcare and Technology Innovation Conference (Business Wire) +8.81%
Mar-13-25 07:40AM	OS Therapies Awarded OST-HER2 Clinical Trial Data Presentation at MIB Agents FACTOR Osteosarcoma Conference (Business Wire)
Mar-11-25 07:40AM	OS Therapies Schedules United Kingdoms Medicines and Healthcare products Regulatory Agency's (MHRA) Scientific Advice Meeting in the Third Quarter of 2025 for Review of its OST-HER2 Immunotherapy Candidate for Osteosarcoma (Business Wire)
Feb-28-25 09:00AM	Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV (ACCESS Newswire)
Feb-26-25 04:01PM	Join OS Therapies Exclusive Live Investor Webinar and Q&A Session on February 27 (Business Wire)
Feb-24-25 07:25AM	OS Therapies Forms Subsidiary OS Drug Conjugates and Initiates Review of Strategic Options for its tunable ADC & Drug Conjugates Platforms (Business Wire)
Feb-20-25 05:00AM	OS Therapies Receives Patent Notice of Allowance from U.S. Patent & Trademark Office Covering Commercial Manufacturing of OST-HER2 (Business Wire)
Feb-14-25 01:51PM	Small-Cap OS Therapies Inks Commercial Manufacture Agreements For Lead Cancer Drug For Rare Type Of Bone Cancer (Benzinga) +12.06%
07:36AM	OS Therapies Initiates Commercial-ready Manufacturing of OST-HER2 to Support Anticipated Biologics Licensing Authorization (BLA) Filing (Business Wire)
Feb-04-25 07:33AM	OS Therapies Provides Corporate Update (Business Wire) +10.29%
Feb-03-25 08:30AM	RedChip Launches RedChat: Revolutionary AI Chatbot for Small-Cap Stock Analysis (ACCESS Newswire)
Jan-30-25 09:35AM	OS Therapies to acquire listeria programs from Ayala Pharmaceuticals (TipRanks) -25.00%
Jan-29-25 10:05AM	OS Therapies Agrees to Acquire All Listeria Monotygenes-based Immuno-Oncology Programs and IP Assets from Ayala Pharmaceuticals, Adding Phase 2 Lung Cancer and Phase 1 Prostate Cancer Programs to Pipeline (Business Wire)
Jan-17-25 08:35AM	OS Therapies price target raised to $15 from $8 at Maxim (TipRanks) -28.40%
Jan-15-25 09:17AM	OS Therapies Announces Phase 2b Clinical Trial of OST-HER2 Achieves Primary Endpoint with Statistical Significance in the Prevention of Recurrent, Fully Resected, Lung Metastatic Osteosarcoma (Business Wire)
Jan-02-25 11:16AM	OS Therapies to Attend the 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-31-24 03:38PM	OS Therapies Announces Closing of $6 Million Private Placement (Business Wire) -8.94%

Show Previous News

OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Grasonville, MD.

FounderMr. Paul A. Romness M.P.H.

Ph.D.Dr. Robert G. Petit II

M.B.A.Mr. Francis Knuettel II

Chief of StaffMr. Jack Doll

Chief Business OfficerMr. Gerald E. Commissiong

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

OSTX

OS Therapies Inc

Upgrade your Finviz experience

All the Features.
Half the Price.